UTHR News and Press, United Therapeutics Corporation From 03/08/22

United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 32 nd Annual Healthcare Conference. T...

Inflation is back. It’s back in a major way. The consumer price index for all items rose 0.6% in January, driving up annual inflation by 7.5%. That marked the biggest gain since February 1982 and was even higher than the Wall Street estimate. (3) It’s taking its toll on everyone...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 42 nd Annual Health Care Conference. The...

Inflation is back. It’s back in a major way. The consumer price index for all items rose 0.6% in January, driving up annual inflation by 7.5%. That marked the biggest gain since February 1982 and was even higher than the Wall Street estimate. (3) It’s taking its toll on everyone...

United Therapeutics Corporation (UTHR) Q4 2021 Earnings Conference Call February 24, 2022, 09:00 AM ET Company Participants Dewey Steadman - Head of IR Martine Rothblatt - Founder, Chairman and CEO Michael Benkowitz - President and COO Conference Call Participants Joseph Thome - Cowen and Com...

I will share the 16-year history of the failed efforts to market inhaled insulin for diabetics. I will explain the potential shortcomings of the United-MannKind Partnership. The readers will be exposed to the growing suspicion about the Achilles' Heel that Technosphere is experien...

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration (FDA) has extended its deadline to May from February to review United Therapeutics' (NASDAQ:UTHR) new drug application (NDA) for Tyvaso DPI. The FDA had requested United Therapeutics additional information regard...

United Therapeutics press release (NASDAQ:UTHR): Q4 Non-GAAP EPS of $3.51 misses by $0.54. Revenue of $415.2M (+7.9% Y/Y) misses by $12.39M. Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Double-digit percentage revenue and patient count growth in full-year 20...

Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Major amendment to Tyvaso DPI™ NDA pushes FDA decision date to May 2022 United Therap...

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $4.05 (+22.4% Y/Y) and the consensus Revenue Estimate is $427.59M (+11.1% Y/Y). Over the last 2 years, UTHR has beaten EPS estimates 75%...